Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Elena Guffart
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Marco Tamborrini
Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Bianca Scherer
Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Anita M Dreyer
Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Arne C Rufer
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Johannes Erny
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Joerg Hoernschemeyer
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Ralf Thoma
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Georg Schmid
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Bernard Gsell
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Araceli Lamelas
Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Joerg Benz
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Catherine Joseph
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Hugues Matile
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
Markus G Rudolph
Roche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
Invasion of erythrocytes by Plasmodial merozoites is a composite process involving the interplay of several proteins. Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein (PfRipr), essential for erythrocyte invasion. Here, we present the crystal structures of PfCyRPA and its complex with the antigen-binding fragment of a parasite growth inhibitory antibody. PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic sialidase fold, but it has no sialidase activity and fulfills a purely non-enzymatic function. Characterization of the epitope recognized by protective antibodies may facilitate design of peptidomimetics to focus vaccine responses on protective epitopes. Both in vitro and in vivo anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in vaccines.